A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
for Large B-cell Lymphoma
37 locations incl. Gilbert
Sponsor: Lyell Immunopharma, Inc.
Sex: All·Age: 18+
Code: NCT07188558·Phase 3·Recruiting·Listed Sep 2025
Medstar Georgetown University Hospital
Clinical research site in Washington D.C., District of Columbia
Part of MedStar Georgetown University Hospital
As of July 2026, 77 paid clinical trials are recruiting at Medstar Georgetown University Hospital in Washington D.C., District of Columbia. Active studies at this site cover conditions such as Malignant Solid Neoplasm, Breast Cancer and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Medstar Georgetown University Hospital (77)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for Triple Negative Breast Cancer
124 locations incl. Birmingham
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
129 locations incl. Daphne
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
for Lumbar Spinal Stenosis
2343 locations incl. Athens
Sponsor: Stryker Instruments
Sex: All·Age: 18+
Code: NCT03072927·Recruiting·Listed Mar 2017
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
for Breast Cancer
134 locations incl. Daphne
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
for Ovarian Cancer
38 locations incl. Mobile
Sponsor: Incyte Corporation
Sex: Female·Age: 18 - 99
Code: NCT07023627·Phase 2·Recruiting·Listed Jun 2025
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
for Large B-cell Lymphoma
60 locations incl. Gilbert
Sponsor: Allogene Therapeutics
Sex: All·Age: 18+
Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
for Intermediate Risk Non-Muscle Invasive Bladder Cancer
49 locations incl. Mobile
Sponsor: Ferring Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06510374·Phase 3·Recruiting·Listed Jul 2024
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
for Parkinsons Disease (PD)
33 locations incl. Sun City
Sponsor: BlueRock Therapeutics
Sex: All·Age: 45 - 75
Code: NCT06944522·Phase 3·Recruiting·Listed Apr 2025
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
39 locations incl. Tucson
Sponsor: Ferring Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06545955·Phase 3·Recruiting·Listed Aug 2024
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
for Relapsed Non-Hodgkin Lymphoma
32 locations incl. Irvine
Sponsor: Lyell Immunopharma, Inc.
Sex: All·Age: 18+
Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
for Non-cystic Fibrosis Bronchiectasis
28 locations incl. Birmingham
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Sex: All·Age: 18 - 80
Code: NCT06559150·Phase 2·Recruiting·Listed Aug 2024
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
for Metastatic HER2-positive Breast Cancer
45 locations incl. Phoenix
Sponsor: Jazz Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06435429·Phase 3·Recruiting·Listed May 2024
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
for MASH - Metabolic Dysfunction-Associated Steatohepatitis
16 locations incl. La Jolla
Sponsor: Madrigal Pharmaceuticals, Inc.
Sex: All·Age: 18 - 75
Code: NCT07335601·Phase 2·Recruiting·Listed Jan 2026
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
for Non-small Cell Lung Cancer (NSCLC)
11 locations incl. Fountain Valley
Sponsor: Genmab
Sex: All·Age: 18+
Code: NCT07288177·Phase 2·Recruiting·Listed Dec 2025
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
for Immune Thrombocytopenia (ITP)
11 locations incl. Los Angeles
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06721013·Phase 1, Phase 2·Recruiting·Listed Dec 2024
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
for Autoimmune Haemolytic Anaemia
23 locations incl. Phoenix
Sponsor: Sanofi
Sex: All·Age: 18+
Code: NCT07086976·Phase 3·Recruiting·Listed Jul 2025
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
16 locations incl. Birmingham
Sponsor: Electra Therapeutics Inc.
Sex: All·Age: 6+
Code: NCT05416307·Phase 2, Phase 3·Recruiting·Listed Jun 2022
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
for Advanced Solid Tumor
19 locations incl. Birmingham
Sponsor: OncoC4, Inc.
Sex: All·Age: 18+
Code: NCT06635785·Phase 1, Phase 2·Recruiting·Listed Oct 2024
Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
for Pressure Ulcers Stage II
13 locations incl. San Diego
Sponsor: ULURU Inc.
Sex: All·Age: 18 - 85·Accepts healthy volunteers
Code: NCT05496296·Recruiting·Listed Aug 2022
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
for Intestinal Failure Associated Liver Disease
13 locations incl. Scottsdale
Sponsor: NorthSea Therapeutics B.V.
Sex: All·Age: 16+
Code: NCT05919680·Phase 2·Recruiting·Listed Jun 2023
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
for Chondral Defect
4 locations incl. Washington D.C.
Sponsor: Vericel Corporation
Sex: All·Age: 17 - 65
Code: NCT06915233·Phase 3·Recruiting·Listed Apr 2025
Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation
for Liver Transplant
10 locations incl. San Francisco
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All·Age: 3 - 13
Code: NCT07549503·Phase 2·Recruiting·Listed Apr 2026
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
for Breast Cancer
1105 locations incl. Anchorage
Sponsor: NRG Oncology
Sex: Female·Age: 18 - 60
Code: NCT05879926·Phase 3·Recruiting·Listed May 2023
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
for Stage III Colon Cancer
922 locations incl. Fairhope
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
for Anatomic Stage II Breast Cancer AJCC v8
776 locations incl. Fairhope
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
for Anatomic Stage I Breast Cancer AJCC v8
585 locations incl. Phoenix
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
for Advanced Esophageal Adenocarcinoma
643 locations incl. Anchorage
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023
Comparing Collared and Collarless Femoral Stems in Primary Total Hip Arthroplasty
for Primary Total Hip Arthroplasty
1 location in Washington D.C.
Sponsor: Medstar Health Research Institute
Sex: All·Age: 18 - 99
Code: NCT07337642·Recruiting·Listed Jan 2026
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
for Acute Lymphoblastic Leukemia
631 locations incl. Anchorage
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 40 - 75·Accepts healthy volunteers
Code: NCT05334069·Recruiting·Listed Apr 2022
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for Chronic Lymphocytic Leukemia
309 locations incl. Tucson
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04269902·Phase 3·Recruiting·Listed Feb 2020
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
for Lung Non-Small Cell Carcinoma
640 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020
Mobile Health for Adherence in Breast Cancer Patients
for Anatomic Stage IV Breast Cancer AJCC v8
459 locations incl. Kingman
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+·Accepts healthy volunteers
Code: NCT06112613·Recruiting·Listed Nov 2023
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for Adenocarcinoma of the Colon
365 locations incl. Fairbanks
Sponsor: NRG Oncology
Sex: All·Age: 45 - 70
Code: NCT05080673·Recruiting·Listed Oct 2021
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
for Childhood Extracranial Germ Cell Tumor
387 locations incl. Birmingham
Sponsor: Children's Oncology Group
Sex: All·Age: All ages
Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for Muscle Invasive Bladder Urothelial Carcinoma
449 locations incl. Phoenix
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
for Bladder Adenocarcinoma
224 locations incl. Phoenix
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT03866382·Phase 2·Recruiting·Listed Mar 2019
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
for Resectable Lung Non-Small Cell Carcinoma
308 locations incl. Fairbanks
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06632327·Phase 3·Recruiting·Listed Oct 2024
E-Mindfulness Approaches for Living After Breast Cancer
for Breast Cancer
357 locations incl. Phoenix
Sponsor: NRG Oncology
Sex: All·Age: 18 - 50
Code: NCT06748222·Phase 3·Recruiting·Listed Dec 2024
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
382 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 5 - 60
Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023
Showing the 40 most relevant of 77 recruiting trials at this site. Browse all with filters →
More research sites in Washington D.C.
- MedStar Washington Hospital Center (96 trials)
- Children's National Medical Center (91 trials)
- Children's National Hospital (79 trials)
- Sibley Memorial Hospital (41 trials)
- Georgetown University (36 trials)
- Georgetown University Medical Center (33 trials)
- George Washington University (19 trials)
- George Washington University Medical Center (19 trials)
- Children's National Health System (11 trials)
- Georgetown Lombardi Comprehensive Cancer Center (11 trials)
Explore more
Paid clinical trials in Washington D.C., DC · District of Columbia clinical trials